Home Cart Sign in  
Chemical Structure| 27220-47-9 Chemical Structure| 27220-47-9

Structure of Econazole
CAS No.: 27220-47-9

Chemical Structure| 27220-47-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Econazole is an imidazole-derived and broad-spectrum antimycotic agent with fungistatic properties, working by inhibiting biosynthesis of ergosterol, thereby damaging the fungal cell wall membrane and altering its permeability.

Synonyms: (±)-Econazol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Econazole

CAS No. :27220-47-9
Formula : C18H15Cl3N2O
M.W : 381.68
SMILES Code : ClC1=CC=C(C(OCC2=CC=C(Cl)C=C2)CN3C=CN=C3)C(Cl)=C1
Synonyms :
(±)-Econazol
MDL No. :MFCD00800993
InChI Key :LEZWWPYKPKIXLL-UHFFFAOYSA-N
Pubchem ID :3198

Safety of Econazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
Nf1/C0//C0 DNSCs 0.1-10 μM 24 hours To evaluate the effect of econazole on the proliferation and apoptosis of Nf1/C0//C0 DNSCs, results showed that econazole significantly reduced cell proliferation and induced apoptosis. PMC10772348
NF1/C0//C0 hiPSC-SCPs 0.15 μM 72 hours To evaluate the inhibitory effect of econazole on the proliferation of NF1/C0//C0 hiPSC-SCPs, results showed that econazole effectively inhibited cell proliferation and induced apoptosis. PMC10772348
Candida albicans ATCC 23866 5.6 ± 0.3 μg/ml To evaluate the in vitro antimycotic activity of econazole and PC-econazole against Candida albicans, showing identical MIC values. PMC105848
Candida albicans ATCC 48867 5.6 ± 0.3 μg/ml To evaluate the in vitro antimycotic activity of econazole and PC-econazole against Candida albicans, showing identical MIC values. PMC105848
Rat aortic rings 1x10^-5 M 8 hours To investigate the effect of Econazole on LPS-induced loss of vascular reactivity, results showed that Econazole partially inhibited the LPS-induced loss of reactivity. PMC1909780
J774 murine macrophage cells 1x10^-5 M 20 hours To investigate the effect of Econazole on LPS-induced iNOS activity, results showed that Econazole significantly inhibited LPS-induced [3H]-citrulline production. PMC1909780
J774 cells 10 μM 4 h Did not alter LPS-induced inducible NO synthase mRNA levels but almost completely abolished nitrite production PMC1910171
J774 cells 1-10 μM 24 h Inhibited LPS-induced nitrite production in a concentration-dependent manner without cytotoxicity PMC1910171
PVN neurones 10 µM Blocked Trpm2 channels, significantly increased overall action current frequency (ACf) and inhibited the temperature effect PMC10618372
Mouse primary choroidal endothelial cells 50 µM 4 hours To validate the protective effect of Econazole in primary cells. Results showed that Econazole significantly increased cell survival. PMC6127142
Fusarium solani 1.0 µg/mL 48 hours Evaluate the effect of NDDS on the antifungal activity of ECZ, results showed that NDDS significantly enhanced the antifungal activity of ECZ PMC6058611
NCI-H520 (squamous cell carcinoma) 22.3 μM 24 hours Econazole significantly decreased the viability of NCI-H520 cells in a dose-dependent manner. PMC5740072
SK-SEM-1 (squamous cell carcinoma) 22.2 μM 24 hours Econazole significantly decreased the viability of SK-SEM-1 cells in a dose-dependent manner. PMC5740072
A549 (adenocarcinoma) 13.5 μM 24 hours Econazole significantly decreased the viability of A549 cells in a dose-dependent manner. PMC5740072
H661 (large cell lung cancer) 6.0 μM 24 hours Econazole significantly decreased the viability of H661 cells in a dose-dependent manner. PMC5740072
RF/6A endothelial cells 1 to 100 µM 4 hours To evaluate the protective effect of Econazole against complement-mediated cell lysis. Results showed that Econazole significantly reduced cell lysis and increased cell survival at concentrations of 10, 20, and 50 µM. PMC6127142

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CBA/J (H-2k) mice Experimental vaginal candidiasis model Topical vaginal administration 0.01 Once daily for five consecutive days To evaluate the therapeutic efficacy of econazole and PC-econazole in treating vaginal candidiasis in mice. Results showed that PC-econazole significantly reduced the C. albicans burden post-treatment, with some mice achieving complete clearance. PMC105848
BALB/C nude mice A549 tumor model Intraperitoneal injection 50 mg/kg Once daily for 21 days Econazole significantly suppressed A549 tumor growth without affecting mouse body weight. PMC5740072
Nude mice Human cNF xenograft model Topical application 1% econazole nitrate cream Twice daily for 24, 48, or 72 hours To evaluate the effect of econazole on apoptosis in tumor tissue in a human cNF xenograft model, results showed that econazole effectively induced apoptosis in tumor tissue. PMC10772348
Japanese white rabbits Fungal keratitis model Topical ocular administration 50 µL of 0.3% w/v Single dose, sustained for 4 hours Evaluate the effect of NDDS on corneal penetration and bioavailability of ECZ, results showed that NDDS significantly increased the concentration of ECZ in the cornea and aqueous humor PMC6058611

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00385502 Onychomycosis Phase 2 Unknown June 2008 United States, Arizona ... More >> Tucson, Arizona, United States, 85741 United States, New York New York, New York, United States, 10032 United States, Oregon Portland, Oregon, United States, 97210 Less <<
NCT03129321 Tinea Pedis Phase 3 Completed - -
NCT03129321 - Completed - -
NCT01696799 Interdigital Tinea Pedis Phase 2 Completed - United States, California ... More >> Therapeutics Inc. San Diego, California, United States, 92123 Less <<
NCT01353976 Tinea Pedis A... More >>thlete's Foot Less << Phase 3 Completed - United States, Florida ... More >> Francisco Flores, MD Miramar, Florida, United States, 33027 United States, Michigan Daniel M. Stewart, DO Clinton Township, Michigan, United States, 48038 United States, Nevada Cyaandi Dove, DPM Las Vegas, Nevada, United States, 89119 United States, Ohio Robert S. Haber, MD South Euclid, Ohio, United States, 44118 United States, South Carolina Cynthia Strout, MD Mt. Pleasant, South Carolina, United States, 29464 United States, Tennessee Michael H. Gold, MD Nashville, Tennessee, United States, 37215 United States, Texas Jeffrey Adelglass, MD Plano, Texas, United States, 75234 Less <<
NCT01353976 - Completed - -
NCT00768599 - Completed - -
NCT00915629 Vaginal Candidiasis Not Applicable Terminated - France ... More >> Pileje 37 Quai de Grenelle, Paris, France, 75015 Less <<
NCT02713893 Healthy Phase 1 Completed - Switzerland ... More >> CROSS Research S.A., Phase I Unit Arzo, Switzerland, CH-6864 Less <<
NCT01358240 Tinea Pedis A... More >>thlete's Foot Less << Phase 3 Completed - United States, California ... More >> Sunil S. Dhawan, MD Fremont, California, United States, 94538 United States, Delaware Guy F. Webster, MD, PhD Hockessin, Delaware, United States, 19707 United States, Florida Marta I. Rendon, MD Boca Raton, Florida, United States, 33486 Jonathan Kantor, MD Jacksonville, Florida, United States, 32204 United States, Minnesota Steven E. Kempers, MD Fridley, Minnesota, United States, 55432 United States, Nebraska Joel Schlessinger, MD Omaha, Nebraska, United States, 68144 United States, Oregon Phoebe Rich, MD Portland, Oregon, United States, 97210 United States, Tennessee Edward J. Primka III, MD Knoxville, Tennessee, United States, 37917 United States, Texas Michael T. Jarratt, MD Austin, Texas, United States, 78759 William Abramovits, MD Dallas, Texas, United States, 75230 United States, Virginia David M. Pariser, MD, FAAD, FACP Norfolk, Virginia, United States, 23507 United States, Wisconsin Harry H. Sharata, MD, PhD Madison, Wisconsin, United States, 53719 Less <<
NCT02720783 Healthy Women Phase 1 Completed - Switzerland ... More >> CROSS Research S.A., Phase I Unit Arzo, Switzerland, CH-6864 Less <<
NCT00768599 Tinea Pedis A... More >>thlete's Foot Less << Phase 2 Completed - United States, California ... More >> Stacy Smith, MD San Diego, California, United States, 92123 United States, Michigan Daniel Stewart, DO Clinton Township, Michigan, United States, 48038 United States, Minnesota Steven Kempers, MD Fridley, Minnesota, United States, 55432 United States, Tennessee Michael Gold, MD Nashville, Tennessee, United States, 37215 United States, Texas Michael Jarratt, MD Austin, Texas, United States, 78759 United States, Utah Leonard Swinyer, MD Salt Lake City, Utah, United States, 84124 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.62mL

0.52mL

0.26mL

13.10mL

2.62mL

1.31mL

26.20mL

5.24mL

2.62mL

References

 

Historical Records

Categories